Bioxcel therapeutics to present an update from its ongoing trial of bxcl701 in aggressive forms of prostate cancer at the 2021 asco genitourinary cancers symposium

New haven, conn., feb. 04, 2021 (globe newswire) -- bioxcel therapeutics, inc. ("bioxcel" or the "company") (nasdaq: btai), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing phase 1b/2 trial of bxcl701, the company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 asco genitourinary ("asco gu") cancers symposium. asco gu is being held from thursday, february 11, 2021 to saturday, february 13, 2021.
BTAI Ratings Summary
BTAI Quant Ranking